本文選題：細菌 + 噬菌體��； 參考：《生物技術通報》2014年07期

【摘要】：抗生素治療盡管有幾十年有效治療的歷史,但隨著越來越多耐/抗藥性細菌的出現(xiàn),細菌對抗生素的抗藥性已成為一個大問題。噬菌體治療是使用噬菌體作為抗菌劑來感染細菌株系,它一直是人們倡導的一個很有前途的常規(guī)抗生素治療的替代方案。然而,由于細菌與噬菌體的協(xié)同進化中,細菌可以通過多種機制獲得對噬菌體的抗性。因此,人們對噬菌體治療抱有期望的同時,也關注噬菌體治療長時間的使用之后,是否會與抗生素使用之后結果相類似,導致抗性細菌病原菌感染的治療困難。綜述了細菌-噬菌體協(xié)同進化中細菌病原菌對有感染能力的噬菌體是否會產生抗性,及其在噬菌體治療中影響的爭論,并展望了噬菌體治療的潛在前景。
[Abstract]:Although antibiotic therapy has a history of effective treatment for several decades, with the emergence of more and more resistant / resistant bacteria, the resistance of bacteria to antibiotics has become a major problem. Bacteriophage therapy is a promising alternative to conventional antibiotic therapy, which uses bacteriophage as an antimicrobial agent to infect bacterial strains. However, because of the co-evolution of bacteriophage and bacteria, bacteria can obtain bacteriophage resistance through a variety of mechanisms. Therefore, people have expectations of phage therapy, but also pay attention to whether the results of bacteriophage therapy after a long period of use will be similar to those after antibiotic use, leading to the difficulty of treatment of resistant bacterial pathogens infection. This paper reviews the debate on whether bacterial pathogens develop resistance to bacteriophages with infectious ability and their influence on phage therapy in the co-evolution of bacteriophage and bacteriophage. The potential prospect of bacteriophage therapy is also prospected.
【作者單位】： 貴州省煙草科學研究院中國煙草分子遺傳重點實驗室;
【基金】：黔煙科合(2012-03),公益性行業(yè)(農業(yè))科研專項經費(201103004)
【分類號】：R378

【相似文獻】

相關碩士學位論文 前1條

1 付鳳洋;中華按蚊不同種群溴氰菊酯抗性生測及機制初步研究[D];重慶師范大學;2013年

，

本文編號：1936129